Appeal No. 2006-0274
Application No. 09/415,890
aqueous secondary solvent;
(c) removing more than 50% of the dipolar aprotic solvent and/or acid and aqueous
secondary solvent; and
(d) reconstituting the solvent vehicle by the addition of a pharmaceutically acceptable
aqueous solvent.
99. The method of claim 97, further comprising the step of dissolving pimaricin in
said dipolar aprotic solvent and/or acid prior to mixing in a pharmaceutically acceptable
aqueous secondary solvent.
116. The method of claim 97, wherein said secondary solvent
comprises aqueous lipid emulsion, water, saline solution, dextrose solution, glacial
acetic acid, or lipid solution.
117. The method of claim 116, wherein said secondary solvent
comprises an aqueous lipid emulsion.
119. The method of claim 117, wherein said aqueous lipid emulsion comprises
an aqueous soy bean lipid emulsion.
133. The method of claim 97, wherein said solvent vehicle comprises anhydrous
N,N-dimethylacetamide and aqueous liquid.
The prior art references cited by the examiner are:
Janoff 6,406,713 June 18, 2002
Szoka 5,277,914 Jan. 11, 1994
Grounds of Rejection
I. Claims 97, 99, 116, 117 and 119 stand rejected under 35 U.S.C. §102(e) over
Janoff.
II. Claims 97, 99, 116, 117, 119 and 133 stand rejected under 35 U.S.C.
§103(a) over Janoff in view of Szoka.
We reverse these rejections.
2
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007